- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting Angiogenesis in Prostate Cancer
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 20, Issue 11, Pages 2676
Publisher
MDPI AG
Online
2019-05-31
DOI
10.3390/ijms20112676
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Human Galectin-1 and its inhibitors: Privileged target for cancer and HIV
- (2019) Narella Sridhar Goud et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Issues and promises of bevacizumab in prostate cancer treatment
- (2018) Vittore Cereda et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2
- (2018) Chloe Peach et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- New Insights in Anti-Angiogenesis in Multiple Myeloma
- (2018) Domenico Ribatti et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Bevacizumab-induced hypertension: Clinical presentation and molecular understanding
- (2018) Megan Li et al. PHARMACOLOGY & THERAPEUTICS
- Hostile takeover: how tumours hijack pre-existing vascular environments to thrive
- (2017) Frank Winkler JOURNAL OF PATHOLOGY
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- (2017) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
- (2017) Nicholas D. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Androgen Receptor and VEGF: Mechanisms of Androgen-Regulated Angiogenesis in Prostate Cancer
- (2017) Kurtis Eisermann et al. Cancers
- Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer
- (2016) Ravi A. Madan et al. BJU INTERNATIONAL
- A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy
- (2016) Rana R. McKay et al. JOURNAL OF CLINICAL ONCOLOGY
- Ten years of anti-vascular endothelial growth factor therapy
- (2016) Napoleone Ferrara et al. NATURE REVIEWS DRUG DISCOVERY
- 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer
- (2016) Freddie C. Hamdy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth
- (2016) X Deng et al. ONCOGENE
- Molecularly Targeted Drugs Plus Radiotherapy and Temozolomide Treatment for Newly Diagnosed Glioblastoma: A Meta-Analysis and Systematic Review
- (2016) Jiahao Su et al. ONCOLOGY RESEARCH
- SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing
- (2016) Athina Mavrou et al. PHARMACOLOGICAL RESEARCH
- Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting
- (2016) E S Antonarakis et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer
- (2016) Marco A. De Velasco et al. Oncotarget
- Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma
- (2015) A. Scholz et al. EMBO Molecular Medicine
- Regulation of vascular endothelial growth factor in prostate cancer
- (2015) S. de Brot et al. ENDOCRINE-RELATED CANCER
- Reconsideration of the clinical and histopathological significance of angiogenesis in prostate cancer: Usefulness and limitations of microvessel density measurement
- (2015) Yasuyoshi Miyata et al. INTERNATIONAL JOURNAL OF UROLOGY
- Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer
- (2015) Yutaka Yamamoto et al. Journal of Translational Medicine
- Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial
- (2015) Daniel P Petrylak et al. LANCET ONCOLOGY
- EGFR Regulates the Development and Microarchitecture of Intratumoral Angiogenic Vasculature Capable of Sustaining Cancer Cell Intravasation
- (2015) Petra Minder et al. NEOPLASIA
- Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy
- (2014) Sanne de Haas et al. ANGIOGENESIS
- Galectin-1 Pulls the Strings on VEGFR2
- (2014) Pamela Stanley CELL
- Serine–arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer
- (2014) A Mavrou et al. ONCOGENE
- Prostate cancer: summary of updated NICE guidance
- (2014) J. Graham et al. BMJ-British Medical Journal
- Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Prostate Cancer: a Systematic Review with Meta-analysis
- (2013) Kai Wang et al. Asian Pacific Journal of Cancer Prevention
- Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales
- (2013) Asmaa E El-Kenawi et al. BRITISH JOURNAL OF PHARMACOLOGY
- Proteomic Characterization of Breast Cancer Xenografts Identifies Early and Late Bevacizumab-Induced Responses and Predicts Effective Drug Combinations
- (2013) E. M. Lindholm et al. CLINICAL CANCER RESEARCH
- Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
- (2013) M. J. Brauer et al. CLINICAL CANCER RESEARCH
- Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer
- (2013) M. Dror Michaelson et al. JOURNAL OF CLINICAL ONCOLOGY
- Prevalence of Prostate Cancer on Autopsy: Cross-Sectional Study on Unscreened Caucasian and Asian Men
- (2013) Alexandre R. Zlotta et al. JNCI-Journal of the National Cancer Institute
- Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial
- (2013) Ian F Tannock et al. LANCET ONCOLOGY
- Androgen up-regulates vascular endothelial growth factor expression in prostate cancer cells via an Sp1 binding site
- (2013) Kurtis Eisermann et al. Molecular Cancer
- The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer
- (2013) Vasundhra Kashyap et al. Molecular Oncology
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Is angiogenesis a hallmark of prostate cancer?
- (2013) Gianluigi Taverna et al. Frontiers in Oncology
- SRPK1 inhibitionin vivo: modulation of VEGF splicing and potential treatment for multiple diseases: Figure 1
- (2012) Sebastian Oltean et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Normal tissues toxicities triggered by combined anti-angiogenic and radiation therapies: hurdles might be ahead
- (2012) M Mangoni et al. BRITISH JOURNAL OF CANCER
- A Unique Galectin Signature in Human Prostate Cancer Progression Suggests Galectin-1 as a Key Target for Treatment of Advanced Disease
- (2012) D. J. Laderach et al. CANCER RESEARCH
- Microvessel density is not increased in prostate cancer: digital imaging of routine sections and tissue microarrays
- (2012) Maria Tretiakova et al. HUMAN PATHOLOGY
- Coordinated Action of Hypoxia-inducible Factor-1α and β-Catenin in Androgen Receptor Signaling
- (2012) Takakazu Mitani et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401
- (2012) William Kevin Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
- Modulation of Akt/mTOR Signaling Overcomes Sunitinib Resistance in Renal and Prostate Cancer Cells
- (2012) P. B. Makhov et al. MOLECULAR CANCER THERAPEUTICS
- Cilengitide Treatment for Malignant Glioma: Current Status and Future Direction
- (2012) Kazuhiko KUROZUMI et al. NEUROLOGIA MEDICO-CHIRURGICA
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- WT1 Mutants Reveal SRPK1 to Be a Downstream Angiogenesis Target by Altering VEGF Splicing
- (2011) Elianna M. Amin et al. CANCER CELL
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Contrast-enhanced ultrasonography for the detection and characterization of prostate cancer: Correlation with microvessel density and Gleason score
- (2011) J. Jiang et al. CLINICAL RADIOLOGY
- Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells
- (2011) Y. Zheng et al. ENDOCRINE-RELATED CANCER
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
- (2011) Karim Fizazi et al. LANCET
- Molecular mechanisms and clinical applications of angiogenesis
- (2011) Peter Carmeliet et al. NATURE
- Molecular control of endothelial cell behaviour during blood vessel morphogenesis
- (2011) Shane P. Herbert et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Lenalidomide in Nonmetastatic Biochemically Relapsed Prostate Cancer: Results of a Phase I/II Double-Blinded, Randomized Study
- (2010) D. Keizman et al. CLINICAL CANCER RESEARCH
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intricacies of Bevacizumab-Induced Toxicities and Their Management
- (2009) Sarah M Gressett et al. ANNALS OF PHARMACOTHERAPY
- Androgen Receptor Controls EGFR and ERBB2 Gene Expression at Different Levels in Prostate Cancer Cell Lines
- (2009) J.-C. Pignon et al. CANCER RESEARCH
- Regulation of Vascular Endothelial Growth Factor (VEGF) Splicing from Pro-angiogenic to Anti-angiogenic Isoforms
- (2009) Dawid G. Nowak et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials
- (2009) David P Dearnaley et al. LANCET ONCOLOGY
- Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors
- (2008) D. G. Nowak et al. JOURNAL OF CELL SCIENCE
- Tumor Angiogenesis
- (2008) Robert S. Kerbel NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now